Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepirovirsen and CHB-TI in chronic hepatitis B
NCT05276297Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2022
- Primary completion
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Small Interfering RNA (siRNA)
- Countries
- 15
01
Overview
Phase 2, randomised, single-blind trial of bepirovirsen and GSK3528869A in Chronic Hepatitis B (CHB) (4 arms), sponsored by GSK. Primary endpoints: Grade 3 Adverse Event, Serious Adverse Event and 2 more. Started Mar 2022; status: completed.
02
Drugs
bepirovirsenGSK3528869A
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05276297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276297.